Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Assay and Drug Development Technologies|April 20, 2004
High-throughput screening with immobilized metal ion affinity-based fluorescence polarization detection, a homogeneous assay for protein kinasesElma E M G Loomans, Antoon M van Doornmalen, Jesse W Y Wat, et al.Journal of Biomolecular Screening|May 30, 2014
High-throughput fluorescence-based screening assays for tryptophan-catabolizing enzymesNicole Seegers, Antoon M van Doornmalen, Joost C M Uitdehaag, et al.Journal of Biomolecular Screening|August 30, 2011
Multidimensional profiling of CSF1R screening hits and inhibitors: assessing cellular activity, target residence time, and selectivity in a higher throughput wayJoost C M Uitdehaag, Cecile M Sünnen, Antoon M van Doornmalen, et al.Plos One|March 22, 2014
Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical useJoost C M Uitdehaag, Jeroen A D M de Roos, Antoon M van Doornmalen, et al.Oncotarget|December 21, 2020
Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascitesJudith E den Ouden, Guido J R Zaman, Jelle Dylus, et al.Plos One|May 29, 2015
Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing DrugsJoost C M Uitdehaag, Jeroen A D M de Roos, Antoon M van Doornmalen, et al.Molecular Cancer Therapeutics|September 3, 2016
Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 InhibitorsJoost C M Uitdehaag, Jeroen A D M de Roos, Martine B W Prinsen, et al.Frontiers in Oncology|October 3, 2022
Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020Jeffrey J Kooijman, Wilhelmina E van Riel, Jelle Dylus, et al.The FEBS Journal|January 20, 2021
Pharmacological validation of TDO as a target for Parkinson's diseasePaula Perez-Pardo, Yvonne Grobben, Nicole Willemsen-Seegers, et al.Frontiers in Immunology|February 15, 2021
Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0Yvonne Grobben, Jos de Man, Antoon M van Doornmalen, et al.Pageof 1